DOUBLE-EXPRESSOR LYMPHOMA
Clinical trials for DOUBLE-EXPRESSOR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DOUBLE-EXPRESSOR LYMPHOMA trials appear
Sign up with your email to follow new studies for DOUBLE-EXPRESSOR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Step attack on aggressive lymphoma shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether a targeted antibody-drug combination (loncastuximab tesirine plus rituximab) followed by standard chemotherapy can improve outcomes for people with high-risk diffuse large B-cell lymphoma. The study enrolls 24 adults with untreated double-exp…
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug targets tough lymphomas in early trial
Disease control Recruiting nowThis early-phase trial tests a drug called pidnarulex (CX-5461) in about 50 people with aggressive B-cell lymphomas that have not responded to standard treatments. The goal is to find the best dose and check if the drug is safe and can shrink tumors. Participants will also have b…
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC